Vanrheenen SM - Search Results

1

Dsl1p, an essential protein required for membrane traffic at the endoplasmic reticulum/Golgi interface in yeast.

Vanrheenen SM, Reilly BA, Chamberlain SJ, Waters MG. Vanrheenen SM, et al. Traffic. 2001 Mar;2(3):212-31. doi: 10.1034/j.1600-0854.2001.020307.x. Traffic. 2001. PMID: 11260526 Free article.

2

Sec35p, a novel peripheral membrane protein, is required for ER to Golgi vesicle docking.

VanRheenen SM, Cao X, Lupashin VV, Barlowe C, Waters MG. VanRheenen SM, et al. J Cell Biol. 1998 Jun 1;141(5):1107-19. doi: 10.1083/jcb.141.5.1107. J Cell Biol. 1998. PMID: 9606204 Free PMC article.

3

Sec34p, a protein required for vesicle tethering to the yeast Golgi apparatus, is in a complex with Sec35p.

VanRheenen SM, Cao X, Sapperstein SK, Chiang EC, Lupashin VV, Barlowe C, Waters MG. VanRheenen SM, et al. J Cell Biol. 1999 Nov 15;147(4):729-42. doi: 10.1083/jcb.147.4.729. J Cell Biol. 1999. PMID: 10562277 Free PMC article.

4

Golgi-to-endoplasmic reticulum (ER) retrograde traffic in yeast requires Dsl1p, a component of the ER target site that interacts with a COPI coat subunit.

Reilly BA, Kraynack BA, VanRheenen SM, Waters MG. Reilly BA, et al. Among authors: vanrheenen sm. Mol Biol Cell. 2001 Dec;12(12):3783-96. doi: 10.1091/mbc.12.12.3783. Mol Biol Cell. 2001. PMID: 11739780 Free PMC article.

5

IcmF and DotU are required for optimal effector translocation and trafficking of the Legionella pneumophila vacuole.

VanRheenen SM, Duménil G, Isberg RR. VanRheenen SM, et al. Infect Immun. 2004 Oct;72(10):5972-82. doi: 10.1128/IAI.72.10.5972-5982.2004. Infect Immun. 2004. PMID: 15385501 Free PMC article.

6

Members of a Legionella pneumophila family of proteins with ExoU (phospholipase A) active sites are translocated to target cells.

VanRheenen SM, Luo ZQ, O'Connor T, Isberg RR. VanRheenen SM, et al. Infect Immun. 2006 Jun;74(6):3597-606. doi: 10.1128/IAI.02060-05. Infect Immun. 2006. PMID: 16714592 Free PMC article.

7

Iron Limitation Triggers Early Egress by the Intracellular Bacterial Pathogen Legionella pneumophila.

O'Connor TJ, Zheng H, VanRheenen SM, Ghosh S, Cianciotto NP, Isberg RR. O'Connor TJ, et al. Among authors: vanrheenen sm. Infect Immun. 2016 Jul 21;84(8):2185-2197. doi: 10.1128/IAI.01306-15. Print 2016 Aug. Infect Immun. 2016. PMID: 27185787 Free PMC article.

8

Applying lessons from the Ebola vaccine experience for SARS-CoV-2 and other epidemic pathogens.

Wolf J, Bruno S, Eichberg M, Jannat R, Rudo S, VanRheenen S, Coller BA. Wolf J, et al. NPJ Vaccines. 2020 Jun 15;5(1):51. doi: 10.1038/s41541-020-0204-7. eCollection 2020. NPJ Vaccines. 2020. PMID: 32566261 Free PMC article. Review.

9

Lessons Learned from the Development and Roll-Out of the rVSVΔG-ZEBOV-GP Zaire ebolavirus Vaccine to Inform Marburg Virus and Sudan ebolavirus Vaccines.

Coller BG, Lapps W Jr, Yunus M, Bruno S, Eichberg MJ, Lee AW, Liu K, Drury R, Millogo J, Macareo LR, Armstrong TH, Blue JT, Isopi LA, Hughes M, VanRheenen SM, Deutsch J, Tell JG, Dubey SA. Coller BG, et al. Among authors: vanrheenen sm. Vaccines (Basel). 2022 Sep 1;10(9):1446. doi: 10.3390/vaccines10091446. Vaccines (Basel). 2022. PMID: 36146524 Free PMC article. Review.

10

Clinical development of a recombinant Ebola vaccine in the midst of an unprecedented epidemic.

Coller BG, Blue J, Das R, Dubey S, Finelli L, Gupta S, Helmond F, Grant-Klein RJ, Liu K, Simon J, Troth S, VanRheenen S, Waterbury J, Wivel A, Wolf J, Heppner DG, Kemp T, Nichols R, Monath TP. Coller BG, et al. Vaccine. 2017 Aug 16;35(35 Pt A):4465-4469. doi: 10.1016/j.vaccine.2017.05.097. Epub 2017 Jun 21. Vaccine. 2017. PMID: 28647166

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

11 results

Search Page

Filters